To overcome these limitations, Antengene developed ATG-201, a “2+1” CD19 x CD3 TCE, which was evaluated in a series of in ...

Clinical-grade CAR-T cell manufacturing was performed in a closed system using a second-generation CD19 vector with 41BB costimulatory domain. Quality control was assessed at different points in the ...